Early studies highlight the promise of prostate-specific membrane antigen-targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guided approaches, supported by high-quality clinical evidence, to translate feasibility into meaningful oncological benefits.
This website uses cookies to ensure you get the best experience on our website.